"Pyrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
| Descriptor ID |
D011720
|
| MeSH Number(s) |
D03.383.129.539
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazoles".
Below are MeSH descriptors whose meaning is more specific than "Pyrazoles".
This graph shows the total number of publications written about "Pyrazoles" by people in this website by year, and whether "Pyrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 5 | 3 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 4 | 1 | 5 |
| 2011 | 3 | 2 | 5 |
| 2012 | 5 | 6 | 11 |
| 2013 | 5 | 3 | 8 |
| 2014 | 6 | 6 | 12 |
| 2015 | 9 | 6 | 15 |
| 2016 | 9 | 12 | 21 |
| 2017 | 11 | 5 | 16 |
| 2018 | 18 | 6 | 24 |
| 2019 | 6 | 10 | 16 |
| 2020 | 8 | 10 | 18 |
| 2021 | 7 | 7 | 14 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 3 | 3 |
| 2024 | 6 | 13 | 19 |
| 2025 | 4 | 5 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazoles" by people in Profiles.
-
Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial. Blood Adv. 2025 Aug 12; 9(15):3728-3738.
-
Functional assessment in patients with castration-resistant prostate cancer treated with darolutamide: results from the DaroAcT study. Oncologist. 2025 Jul 04; 30(7).
-
Late Recurrence of Spindle Cell Sarcoma in Association with TPM3::NTRK1 Fusion. Int J Surg Pathol. 2025 Dec; 33(8):1709-1712.
-
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer. Endocr Relat Cancer. 2025 Jun 01; 32(6).
-
Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025 Apr 14; 43(4):740-756.e8.
-
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenstr?m macroglobulinemia. Blood Adv. 2025 Feb 25; 9(4):722-728.
-
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. J Clin Endocrinol Metab. 2025 Feb 18; 110(3):e600-e606.
-
Zanubrutinib for the treatment of Bing-Neel syndrome. Br J Haematol. 2025 Apr; 206(4):1136-1140.
-
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 02 06; 145(6):612-624.